HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

bafetinib

a potent and selective dual Bcr-Abl/Lyn tyrosine kinase inhibitor is an agent for imatinib-resistant leukemia; structure in first source
Also Known As:
INNO-406; NS-187
Networked: 18 relevant articles (1 outcomes, 5 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1. Kimura, Shinya: 3 articles (06/2010 - 12/2005)
2. Maekawa, Taira: 3 articles (02/2007 - 12/2005)
3. Cortes, Jorge: 2 articles (12/2010 - 06/2010)
4. Kantarjian, Hagop: 2 articles (12/2010 - 06/2010)
5. Ashihara, E: 2 articles (11/2008 - 09/2007)
6. Kimura, S: 2 articles (11/2008 - 09/2007)
7. Kawata, E: 2 articles (11/2008 - 09/2007)
8. Kuroda, J: 2 articles (11/2008 - 09/2007)
9. Maekawa, T: 2 articles (11/2008 - 09/2007)
10. Kamitsuji, Y: 2 articles (11/2008 - 09/2007)

Related Diseases

1. Leukemia
2. BCR-ABL Positive Chronic Myelogenous Leukemia (Chronic Myelogenous Leukemia)
3. Neoplasms (Cancer)
4. Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia)
5. B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia)

Related Drugs and Biologics

1. imatinib (Gleevec)
2. Protein-Tyrosine Kinases (Tyrosine Kinase)
3. Phosphotransferases (Kinase)
4. dasatinib (BMS 354825)
5. 4- methyl- N- (3- (4- methylimidazol- 1- yl)- 5- (trifluoromethyl)phenyl)- 3- ((4- pyridin- 3- ylpyrimidin- 2- yl)amino)benzamide (nilotinib)
6. bafetinib
7. sunitinib (Sutent)
8. gefitinib (Iressa)
9. bortezomib (Velcade)
10. MART-1 Antigen

Related Therapies and Procedures

1. Stents